Q1 EPS Estimate for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at HC Wainwright lifted their Q1 2027 earnings estimates for Corcept Therapeutics in a research note issued to investors on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.85 per share for the quarter, up from their prior estimate of $0.44. HC Wainwright has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.53 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2027 earnings at $1.28 EPS, Q3 2027 earnings at $1.54 EPS, Q4 2027 earnings at $1.70 EPS, FY2027 earnings at $5.38 EPS, FY2028 earnings at $7.70 EPS, FY2029 earnings at $10.35 EPS and FY2030 earnings at $13.49 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.Corcept Therapeutics’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 earnings per share.

A number of other equities analysts have also recently commented on CORT. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research report on Thursday. Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Piper Sandler lifted their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Corcept Therapeutics Price Performance

CORT stock opened at $69.49 on Monday. The company has a fifty day moving average price of $48.02 and a two-hundred day moving average price of $52.14. Corcept Therapeutics has a one year low of $28.66 and a one year high of $91.00. The stock has a market cap of $7.46 billion, a price-to-earnings ratio of 198.55 and a beta of 0.50.

Insider Buying and Selling

In other news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $51.83, for a total value of $1,036,600.00. Following the completion of the sale, the insider owned 2,231 shares of the company’s stock, valued at approximately $115,632.73. The trade was a 89.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sean Maduck sold 75,000 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the completion of the sale, the insider directly owned 8,977 shares of the company’s stock, valued at approximately $588,801.43. The trade was a 89.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 166,198 shares of company stock valued at $9,132,019 in the last 90 days. 20.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors have recently modified their holdings of the business. Parallel Advisors LLC boosted its position in shares of Corcept Therapeutics by 2.5% in the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after acquiring an additional 96,763 shares during the period. State Street Corp lifted its position in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after purchasing an additional 15,656 shares during the period. Geode Capital Management LLC lifted its position in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the period. First Trust Advisors LP lifted its position in Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares during the period. Finally, Morgan Stanley lifted its position in Corcept Therapeutics by 34.1% during the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock worth $55,404,000 after purchasing an additional 405,081 shares during the period. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.